A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Inclusion Criteria: -Patients with renal impairment: mild, moderate, severe and patients on hemodialysis) that has been stable OR * Healthy Subjects: * Have normal renal function * No evidence of any disease or condition that may affect pharmacokinetics of FEP-TAZ. Exclusion Criteria: * Evidence of hepatorenal or nephritic syndrome * Any clinically significant abnormal findings on medical history, physical examination,or clinical laboratory tests (other than those associated with controlled diabetes,hypertension, hypercholesterolemia, dyslipidemia, or renal impairment or related or causative diseases)